Oncology

Oncology pharmacists are increasingly shaping patient care.

New research highlights abemaciclib and ribociclib as promising treatments for early HR-positive, HER2-negative breast cancer, emphasizing survival benefits and adverse effects.

Combination therapy with tremelimumab and durvalumab significantly improves survival in patients with liver cancer compared with standard sorafenib treatment.

Morgan Cantley, PharmD, BCOP, shares key insights about the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan.

Many adults remain unaware of HPV's cancer risks, highlighting the urgent need for increased awareness.

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

Pharmacists optimize biosimilar and 505(b)(2) use through collaboration, education, and integration.

Acalabrutinib shows improved safety and survival rates in chronic lymphocytic leukemia (CLL), reducing risks of mortality and cardiovascular complications.

Oncology pharmacists can lead value-based care integration under EOM with data-driven strategies.

TAR-200 shows promise in treating BCG-unresponsive bladder cancer, achieving 82% tumor elimination and offering new hope for patients.

New research links high perilipin 2 expression in lung adenocarcinoma to aggressive disease progression and shorter survival, highlighting potential treatment targets.

BV-R2 combination shows survival benefit across high-risk subgroups.

Natural compounds like Prunus armeniaca and bee venom enhance breast cancer treatment, boosting efficacy and reducing adverse effects.

Pharmacists play a crucial role in improving vaccination rates among patients with cancer, addressing barriers, and enhancing patient education in oncology care.

Oncology pharmacists could be canaries in the coal mine of health care systems.

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.

Amy C. Nieto delves into the latest advancements in non-small cell lung cancer (NSCLC) treatment, including sunvozertinib, a newly-approved therapy for challenging EGFR exon 20 insertion mutations.

Individuals who have survived childhood cancer had a higher risk of developing a severe COVID-19 infection, while exhibiting a lower risk of contracting the virus.

The action is supported by positive safety and efficacy findings from the phase 1a/1b first-in-human Beamion LUNG-1 trial.

Recent advances in GI oncology offer new treatment options for colorectal and pancreatic cancers, enhancing patient care and pharmacist roles in management.

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Recent data link a higher consumption of ultraprocessed food to increased lung cancer risk, highlighting the need for dietary changes and further research.

CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.

Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.

PHESGO reduced patient infusion time from 90 minutes to as few as 5, enhancing patient experience while maintaining efficacy and safety.

August marks a pivotal time for oncology pharmacy, blending transitions, celebrations, and new beginnings as professionals prepare for the upcoming season.

Herzuma shows promising efficacy and safety as a cost-effective biosimilar for treating HER2+ advanced gastric cancer, offering new hope for patients.